Insider Buying: Biodesix (NASDAQ:BDSX) Director Buys 15,000 Shares of Stock

August 14, 2026 by InsiderTrades.com

Key Points

Director buying: Biodesix director Jack Schuler purchased 15,000 shares for approximately $367,050 at $24.47 per share, raising his direct ownership to 555,810 shares. His purchases over three sessions totaled 42,600 shares worth about $1.03 million.
Quarterly results beat expectations: Biodesix reported a quarterly loss of $0.71 per share versus the expected $0.90 loss, while revenue of $26.86 million exceeded the $26.03 million consensus estimate.
Positive outlook but significant risks: Analysts maintain a “Moderate Buy” consensus with an average price target of $31.33, but the company remains unprofitable, carries a 5.12 debt-to-equity ratio, and is forecast to post a $2.68 per-share loss for the year.

Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) Director Jack Schuler acquired 15,000 shares of the stock in a transaction dated Wednesday, August 12th. The shares were bought at an average cost of $24.47 per share, with a total value of $367,050.00. Following the transaction, the director directly owned 555,810 shares of the company's stock, valued at $13,600,670.70. This represents a 2.77% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Biodesix Price Performance

Shares of NASDAQ BDSX opened at $23.79 on Friday. The company has a fifty day moving average price of $20.33 and a 200 day moving average price of $16.13. The firm has a market cap of $250.98 million, a PE ratio of -7.50 and a beta of 0.56. The company has a current ratio of 2.85, a quick ratio of 2.85 and a debt-to-equity ratio of 5.12. Biodesix, Inc. has a 1-year low of $5.26 and a 1-year high of $25.52.

Biodesix (NASDAQ:BDSX - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.19. The firm had revenue of $26.86 million for the quarter, compared to the consensus estimate of $26.03 million. Biodesix had a negative return on equity of 788.19% and a negative net margin of 26.97%. Research analysts predict that Biodesix, Inc. will post -2.68 earnings per share for the current fiscal year.

Trending Headlines about Biodesix

Here are the key news stories impacting Biodesix this week:

Positive Sentiment: Director Jack W. Schuler purchased an additional 15,000 shares for approximately $367,050 at an average price of $24.47 on August 12. Combined with purchases of 13,700 shares on August 11 and 13,900 shares on August 10, Schuler bought 42,600 shares for roughly $1.03 million over three sessions, increasing his direct ownership to 555,810 shares. The buying may signal confidence in Biodesix’s outlook. SEC insider transaction filing
Positive Sentiment: Biodesix reported second-quarter adjusted performance that exceeded expectations: EPS was negative $0.71 versus the consensus estimate of negative $0.90, while revenue reached $26.86 million compared with an expected $26.03 million. The earnings call transcript provides additional discussion of the results and outlook. Biodesix Q2 2026 earnings call transcript
Positive Sentiment: Analyst sentiment remains constructive. Canaccord Genuity raised its price target from $27 to $35 while maintaining a Buy rating, and HC Wainwright reiterated Buy with a $27 target. Roth Capital previously initiated coverage with a Buy rating and a $32 target. The reported consensus target is $31.33, above recent trading levels. Biodesix analyst price-target coverage
Neutral Sentiment: Institutional ownership activity was mixed but included several new positions and additions, including AIGH Capital Management’s approximately $11.0 million stake and increased holdings by XTX Topco. Institutions own about 21% of BDSX.
Negative Sentiment: Despite the revenue and EPS beat, Biodesix remains unprofitable, with a negative net margin and analysts forecasting approximately negative $2.68 EPS for the current year. Its debt-to-equity ratio of 5.12 also represents a financial risk, particularly after the stock’s substantial advance toward its 52-week high.

Wall Street Analysts Forecast Growth

BDSX has been the topic of a number of research reports. HC Wainwright reissued a "buy" rating and issued a $27.00 price objective (up from $26.00) on shares of Biodesix in a research report on Thursday, August 6th. Canaccord Genuity Group boosted their price target on shares of Biodesix from $27.00 to $35.00 and gave the stock a "buy" rating in a research report on Monday. Weiss Ratings upgraded Biodesix from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, June 12th. Finally, Roth Capital started coverage on Biodesix in a report on Wednesday, June 24th. They set a "buy" rating and a $32.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $31.33.

View Our Latest Analysis on Biodesix

Institutional Investors Weigh In On Biodesix

Large investors have recently added to or reduced their stakes in the business. AIGH Capital Management LLC bought a new position in Biodesix during the first quarter worth $10,996,000. XTX Topco Ltd increased its holdings in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock valued at $58,000 after purchasing an additional 102,494 shares during the last quarter. Monashee Investment Management LLC raised its position in shares of Biodesix by 12.3% in the fourth quarter. Monashee Investment Management LLC now owns 112,344 shares of the company's stock valued at $764,000 after purchasing an additional 12,348 shares during the period. Walleye Capital LLC bought a new position in shares of Biodesix in the second quarter valued at about $1,679,000. Finally, Stempoint Capital LP acquired a new stake in shares of Biodesix during the 1st quarter worth about $1,015,000. Institutional investors own 20.96% of the company's stock.

About Biodesix

(Get Free Report)

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company's flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.